retatrutide phase 🚨 2 is out: 24.2% mean weight loss and a quarter lost >30%! Women lost more weight than men. #ADA2023 was like drinking from a fire hose for emerging anti-obesity retatrutide phase 3 #obesity #osteoarthritis

Retatrutide maintenance protocols are still being worked out but a similar step-down approach to 4 to 8 mg weekly is the expected model

Ongoing Phase 3 trials are evaluating retatrutide in knee osteoarthritis (where weight-independent anti-inflammatory effects have been observed), obstructive sleep apnea, and non-alcoholic steatohepatitis

Whether you prefer mornings, evenings, or tying it to meals, the key is staying consistent and listening to how your body responds

(2023) Pharmacokinetics and pharmacodynamics of retatrutide, a GIP, GLP-1, and glucagon receptor agonist Clinical Pharmacokinetics PubMed ID: 37542643 Common questions FAQ What is Retatrutide (RETA)

A clean visual introduction to Retatrutide as a triple receptor research peptide

For patients taking warfarin , routine INR monitoring should continue as per established protocols